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ABSTRACT
Objective: Exogenously administered CO interferes with PMN
recruitment to the inflamed organs. The mechanisms of CO-
dependent modulation of vascular proadhesive phenotype, a key
step in PMN recruitment, are unclear.
Methods: We assessed the effects/mechanisms of CO liberated
from a water-soluble CORM-3 on modulation of the proadhesive
phenotype in hCMEC/D3 in an in vitro model of endotoxemia. To
this end, hCMEC/D3 were stimulated with LPS (1 lg/mL) for six
hours. In some experiments hCMEC/D3 were pretreated with
CORM-3 (200 lmol/L) before LPS-stimulation. PMN rolling/
adhesion to hCMEC/D3 were assessed under conditions of laminar
shear stress (0.7 dyn/cm2). In parallel, expression of adhesion
molecules E-selectin, ICAM-1, and VCAM-1 (qPCR), activation of
transcription factors, NF-jB and AP-1 (ELISA), and MAPK-
signaling (expression/phosphorylation of p38, ERK1/2, and JNK1/
2; western blot) were assessed.
Results: The obtained results indicate that CORM-3 pretreatment
reduces PMN rolling/adhesion to LPS-stimulated hCMEC/D3
(p < 0.05). Decreased PMN rolling/adhesion to hCMEC/D3 was
associated with CORM-3-dependent inhibition of MAPK JNK1/2
activation (Tyr-phosphorylation), inhibition of transcription factor,
AP-1 (c-Jun phosphorylation), and subsequent suppression of
VCAM-1 expression (p < 0.05).
Conclusions: These findings indicate that CORM-3 pretreatment
interferes with JNK/AP-1 signaling and suppresses LPS-induced
upregulation of the proadhesive phenotype in hCMEC/D3.
KEY WORDS: carbon monoxide, CORM, transcription factors, E-
selectin, VCAM-1, ICAM-1, anti-inflammatory, adhesion molecules,
brain circulation, sepsis
Abbreviations used: AP-1, activator protein-1; BBB, blood–brain
barrier; CBF, cerebral blood flow; CO, carbon monoxide; COHb,
carboxyhemoglobin; CORM-3, CO-releasing molecule-3; CPP,
cerebral perfusion pressure; CVECs, cerebrovascular endothelial
cells; hCMEC/D3, human-derived cerebral microvascular endothe-
lial cells; HO, heme-oxygenase; ICAM-1, intercellular adhesion
molecule 1; iCORM-3, inactivate CORM-3; LPS, lipopolysaccharide;
MAPK, mitogen-activated protein kinase; MPO, myeloperoxidase;
NF-jB, nuclear factor kappa B; PBS, phosphate buffered saline;
PI3K, phosphatidylinositol-3-kinase; PMN, polymorphonuclear
leukocytes; qPCR, quantitative polymerase chain reaction; SAE,
sepsis-associated encephalopathy; VCAM-1, vascular cell adhesion
molecule 1.
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INTRODUCTION
Severe sepsis is a leading killer of patients in intensive care
units with an estimated mortality of 45% [24]. Brain
dysfunction associated with severe sepsis is termed SAE;
coma related to SAE is an independent predictor of death in
severe sepsis [12,39,51]. A possible contributor to SAE is
inflammation instigated by circulating bacterial products
(e.g., LPS) that affect the cerebrovascular endothelium of the
BBB.
One of the key features of severe sepsis is an overwhelming
recruitment of PMN to the affected organs [34]. PMN
recruitment to the brain, however, is minimized due to
presence of the BBB and higher shear stress in the brain
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circulation under euvolemic conditions [21]. However, CPP
in septic patients is decreased and CBF is reduced indepen-
dent of changes in either blood pressure or cardiac output
[1]. Septic patients are typically intravascularly depleted and
experience lower shear stress in the brain microcirculation
due to decreased driving pressure, thus potentially exacer-
bating leukocyte–endothelial cell interaction. In experimental
models, challenging the cerebrovascular endothelium with
sepsis-relevant stimulus(i) upregulates proadhesive pheno-
type resulting in increased interaction (e.g., rolling/adhesion)
with circulating PMN [58]. The latter interactions may
further activate cerebrovascular endothelium and contribute
to the BBB dysfunction. Indeed, PMN recruitment to the
brain perivascular space and formation of the perivascular
edema has been demonstrated in sepsis animal models
[9,58,59]. Therefore, targeting leukocyte–endothelial cell
adhesive interactions during early onsets of sepsis is an
attractive therapeutic approach to suppress/prevent SAE.
Endogenously produced CO (as a product of heme
oxygenase-1, HO-1, activity) is recognized as a signaling
molecule with potent anti-inflammatory effects [28]. How-
ever, therapeutic use of inhaled CO is limited due to
potential formation of COHb to toxic levels [13]. Recently,
CORMs [transition metal carbonyls capable of carrying/
releasing CO] were synthesized and demonstrated beneficial
effects in suppressing/preventing inflammatory response(s)
in various tissues employing both in vitro and in vivo
experimental approaches [3,7,14,28]. Importantly, the ben-
eficial effects of systemically administered CORMs are
achieved without increasing COHb to toxic levels
[10,28,29,31,19].
Recent findings indicate that anti-inflammatory effects of
CORMs are largely attributed to their ability to suppress the
leukocyte (e.g., PMN) proadhesive/promigratory phenotype
resulting in reduced PMN recruitment and suppression of
sepsis-relevant inflammation [3,26,54]. However, the ability
of CORMs (in particular, water-soluble CORM-3) to mod-
ulate vascular endothelial cell inflammatory activation/dys-
function is controversial and requires further investigation.
Moreover, no studies to date investigated CORM-dependent
modulation of PMN interaction with human CVECs.
Therefore, in this study we assessed CORM-3-dependent
modulation of hCMEC/D3 [55] proadhesive phenotype and
subsequent adhesive interactions (e.g., rolling/adhesion) with
human-derived PMN under experimental conditions of flow
in an in vitro model of acute endotoxemia.
MATERIALS AND METHODS
Ethics
The study was approved by the Office of Research Ethics at
Western University (London, Ontario, Canada).
Cell Culture
hCMEC/D3 represent a stable, fully characterized, and well-
differentiated human brain endothelial cell line [55]. hCMEC/
D3 were kindly provided by Dr. P. Couraud (INSERM,
Institute Cochin, Paris, France) and cultured on collagen-I-
coated cell culture dishes (Sarstedt) in phenol-red-free
Vasculife Basal Medium (LifeLine Cell Technology, Walk-
ersville, MD, USA) supplemented with microvascular endo-
thelial cell growth factors (VascuLife EnGS-Mv kit; LifeLine
Cell Technology), 5% fetal calf serum, and penicillin/strep-
tomycin (Wisent Bioproducts, St-Bruno, QC, Canada; 100 U/
mL and 100 lg/mL, respectively) in humidified room air
supplemented with 5% CO2 (cell culture incubator RCO
000T-9-ABC; Kendro Laboratory Products, Asheville, NC,
USA). hCMEC/D3 at passages 35–40 were used for the
experiments.
Carbon Monoxide-Releasing Molecule-3
Carbon monoxide-releasing molecule-3 [CORM-3, Ru
(CO)3Cl(glycinate); molecular weight 294.61] was synthe-
sized by Dr. Alfredo Capretta (McMaster University, Ham-
ilton, ON, Canada) as described in [25]. Stock solutions of
CORM-3 (10 mmol/L) were prepared in double-distilled
water. iCORM-3 was prepared by leaving CORM-3 in
Dulbecco’s PBS (DPBS; pH 7.4) buffer overnight at room
temperature to liberate all CO from the molecule [54].
Protocols
For various experimental end points, hCMEC/D3 were seeded
on specific cell culture dishes (see below) and cultured for
48 hours. In some experiments, hCMEC/D3 were pretreated
for two hours with CORM-3 or iCORM-3 (200 lmol/L)
before stimulation with LPS (Escherichia coli 055:B5; Sigma-
Aldrich, Oakville, ON, Canada) (1 lg/mL) for six hours. In
some experiments, hCMEC/D3 cells were pretreated with a
selective JNK inhibitor [11] (SU3327; TOCRIS) (25 nM) for
30 minutes before stimulation with LPS.
PMN Rolling/Adhesion Assay
PMN-hCMEC/D3 adhesive interactions (i.e., rolling/adhe-
sion) were assessed employing parallel flow perfusion slides
(l-Slide IV0.4; [11]) and using 0.7 dyn/cm2 laminar fluid
shear stress to mimic pathophysiological (i.e., hypoperfused)
status of the brain microcirculation [15,26,36]. To this end,
hCMEC/D3 were grown in the l-Slide IV0.4 channels for
48 hours and pretreated/stimulated with CORM-3/LPS,
respectively. Subsequently, the slides were transferred and
mounted on to inverted microscope (DIAPHOT 300, Nikon)
equipped with the air-heated (37°C) chamber. l-Slide IV0.4
channels containing hCMEC/D3 were connected to the
syringe pump (Harvard Apparatus 22) and perfused with the
cell culture medium for five minutes. Subsequently, human-
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derived PMN [freshly isolated from healthy volunteers as
previously described by us (Mizuguchi, 2009 #13)] were
added to the medium (1 9 106 cells/mL) and perfused over
the endothelial monolayers for additional five minutes.
PMN-hCMEC/D3 adhesive interactions were video-recorded
in five randomly selected fields (30 sec/field) starting at
2.5 minutes time point following initiation of the PMN
perfusion. PMN rolling/adhesion was video-analyzed after
the experiment and expressed as “number of PMN rolling/
adhesion/0.1 mm2/min.” PMNs with the rolling velocities
less than 100 lm/sec were considered as “rolling PMN,” and
PMN that remain stationary for more than 10 seconds were
considered as “adherent PMN.”
qPCR
hCMEC/D3 (4 9 105 cells) were seeded in six-well plates (BD
Falcon) 48 hours before the experiment, then pretreated/
stimulated with CORM-3/LPS, respectively. Subsequently,
hCMEC/D3 were washed once with PBS before total RNA
extraction using TRIzol (Life Technologies, Burlington, ON,
Canada) according to the manufacturer’s protocol. iScriptTM
Reverse Transcription Supermix (Bio-Rad, Mississauga, ON,
Canada) was used to produce cDNA from 1 lg total RNA
according to the manufacturer’s protocol. SsoFASTTM Probes
Supermix was purchased from BIO-RAD and five prede-
signed human gene-specific primers; E-selectin (Assay ID:
Hs00950401_m1), ICAM-1 (Assay ID: Hs00164932_m1),
VCAM-1 (Assay ID: Hs01003372_m1), GAPDH (Assay ID:
Hs02758991_g1) and 18S (Assay ID: Hs99999901_s1) were
purchased from Applied Biosystems/Life Technologies (Taq-
Man Gene Expression Assays). Dilution curves of represen-
tative cDNA samples were used to determine conditions
resulting in 95–105% amplification efficiency which were
subsequently used for experimental samples. qPCR was
carried out on a CFX96 Real-Time System (Bio-Rad) using
an initial 95°C incubation for 30 seconds and 40 cycles of: five
seconds at 95°C and 15 seconds at 60°C. Relative expression
values were determined by normalization to GAPDH and
18 seconds using Bio-Rad CFX Manager v 3.1 Gene Study
application and the mean target stability values for the
reference genes were determined to be M < 0.5. For statistics,
the mean expression, SEM and n value were imported into
GraphPad Prism 4.03 (La Jolla, CA, USA) and analyzed using
one-way ANOVA on each gene. Results were considered
significant when p < 0.05.
Western Blot
hCMEC/D3 were grown in six-well cell culture plates (BD
Falcon, Mississauga, ON, Canada) and pretreated/stimulated
with CORM-3/LPS, respectively. Subsequently, the cells were
washed with PBS and lysed in a hot 2X concentrated sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample-loading buffer. Total cellular proteins were
resolved on 8% SDS-PAGE and transferred to polyvinylidene
difluoride membranes as described elsewhere. The mem-
branes were blocked for one hour in 5% skim milk and 0.1%
Tween 20 (Sigma-Aldrich) and incubated for one hour with
primary antibodies directed against phosphorylated-p38
(phospho-p38: ab32557), ERK (phospho-ERK: ab50011),
JNK1/2 (phospho-JNK1/2: ab4821) MAPK, respectively. For
protein loading, control membranes were probed with mouse
monoclonal antibody against GAPDH (ab8245). All primary
antibodies were purchased from Abcam Inc. (Toronto, ON,
Canada). Protein bands were visualized employing secondary
horse radish peroxidase-conjugated anti-mouse (#616520;
Invitrogen, Burlington, ON, Canada) or anti-rabbit (#656120;
Invitrogen) antibody and enhanced chemiluminescence
approach. Band intensities were captured using a Micro-
Chemi imaging system (Froggabio, Toronto, Canada) and
quantified using GelQuant Pro Software (FroggaBio).
ELISA Assays for NF-jB and AP-1 (c-Jun)
Activation
hCMEC/D3 were grown in six-well plates for 48 hours and
pretreated with either CORM-3 or iCORM-3 for two hours.
Subsequently, the cells were stimulated with LPS (1 lg/mL)
for one hour and processed for assessment of NF-jB activa-
tion. In parallel, cells were stimulated with LPS for 30 min and
collected for assessment of AP-1 activation. In each ELISA
assay, PathScan Phospho-NF-jB p65 (Ser536) Sandwich
ELISA Kit (#7173) and PathScan Phospho-c-Jun (Ser63)
Sandwich ELISA Kit II (#7145) (both from Cell Signaling
Technology) were used in accordance to the manufacturer’s
instruction. The ELISA reactions were read at 450 nm
wavelengths using microplate reader (Bio-Rad, model 680).
Statistical Analysis
Statistical analyses were performed with StatMate IV and
data are presented as mean  SE for the indicated number
of separate experiments. All analyses were based on more
than four separate experiments. Differences between groups
were determined by analysis of variance (ANOVA) and
Tukey’s correction. p-value of less than 0.05 was considered
statistically significant.
RESULTS
PMN Rolling/Adhesion Assay
Stimulation of hCMEC/D3 with LPS (1 lg/mL) for six hours
resulted in an increase in PMN rolling and adhesion in the
presence of fluid shear stress (Figure 1). Pretreatment of
hCMEC/D3 with CORM-3 effectively suppressed both LPS-
induced PMN rolling and adhesion to hCMEC/D3. In these
experiments, CORM-3 reduced PMN rolling by 54.9% and
PMN adhesion by 45.7% as compared to the positive control
(i.e., LPS-stimulated hCMEC/D3 only) (Figure 1, n = 4;
F. Serizawa et al.
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p < 0.05). Pretreatment of hCMEC/D3 with iCORM-3 did
not suppress LPS-induced PMN rolling/adhesion.
Adhesion Molecule Expression
To test whether CORM-3-pretreatment suppressed PMN
rolling/adhesion to LPS-stimulated hCMEC/D3 is a conse-
quence of CORM-3-dependent modulation of hCMEC/D3
proadhesive phenotype (e.g., reduced levels of cell adhesion
molecule expression), hCMEC/D3 were analyzed for expres-
sion of E-selectin, ICAM-1, and VCAM-1 employing a qPCR
approach. Stimulation of hCMEC/D3 with LPS resulted in
upregulation of E-selectin, ICAM-1, and VCAM-1 expression
(Figure 2A–C). Pretreatment of hCMEC/D3 with CORM-3
but not with iCORM-3 effectively suppressed expression
of VCAM-1 (p < 0.05) (Figure 2C), however, failed to
reduce LPS-induced expression of E-selectin and ICAM-1
(Figure 2A,B).
NF-jB and AP-1 Activation
Next, we assessed the effects of CORM-3-derived CO on
modulation of two key inflammation-relevant transcription
factors, NF-jB and AP-1, involved in upregulation of the
adhesion molecule expression in numerous models of
inflammation [23,56]. Stimulation of hCMEC/D3 with
LPS-induced activation of AP-1 as evidenced by the increase
in c-Jun Ser63-phosphorylation levels (p < 0.05) (Figure 3).
Pretreatment of hCMEC/D3 with CORM-3 effectively sup-
pressed LPS-induced activation of AP-1 (p < 0.05) (Fig-
ure 3), however, failed to interfere with LPS-induced
activation of NF-jB, as assessed by LPS-induced changes in
p65 p-Ser536 levels (Figure 4). In both experiments iCORM-
3 had no effect neither on LPS-induced phosphorylation
levels of AP-1 nor NF-jB (Figures 3 and 4, respectively).
MAPK Activation
MAPKs participate in LPS-induced signal transduction and
play a key role in activation of AP-1 [5,57]. Therefore, we
assessed whether CORM-3-derived CO can modulate MAPK
p38, ERK1/2, and JNK1/2 activation following stimulation
with LPS. Pretreatment of hCMEC/D3 with CORM-3 (but
Figure 1. CORM-3 suppresses PMN rolling/adhesion to LPS-stimulated
hCMEC/D3. hCMEC/D3 were grown in the channels of the parallel flow
perfusion slides. Confluent hCMEC/D3 monolayers were pretreated (Pre-)
for two hours with CORM-3 or iCORM-3 (200 lmol/L) before stimulation
with LPS (1 lg/mL) for six hours. Subsequently, PMN (1 9 106/mL) were
perfused over hCMEC/D3 in the presence of 0.7 dyn/cm2 laminar shear
stress. PMN rolling/adhesion were assessed following five minutes of
perfusion. n = 4, *p < 0.05 as compared to corresponding nontreated
cells, #p < 0.05 as compared to corresponding LPS-stimulated cells and
LPS/iCORM-3-treated cells.
A
B
C
Figure 2. CORM-3 reduces adhesion molecule expression in LPS-stimu-
lated hCMEC/D3. Confluent hCMEC/D3 were pretreated (Pre-) for two
hours with CORM-3 or iCORM-3 (200 lmol/L) and stimulated with LPS
(1 lg/mL) for six hours. Subsequently, expression of E-selectin, ICAM-1,
and VCAM-1 were assessed by qPCR. n = 5, *p < 0.05 as compared to
corresponding nontreated cells, #p < 0.05 as compared to corresponding
LPS-stimulated cells and LPS/iCORM-3-treated cells.
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not iCORM-3) significantly reduced LPS-induced activation
of JNK1/2 in a dose-dependent manner (Figure 5). In
contrast, CORM-3 failed to suppress LPS-induced phos-
phorylation of p38 and ERK1/2 (data not shown).
To further delineate the role of JNK1/2 signaling in
modulation of the proadhesive/proinflammatory phenotype
in hCMEC/D3, parallel experiments were performed employ-
ing selective JNK inhibitor, SU3327. Pretreatment of
hCMEC/D3 with SU3327 (25 nM) in a similar manner as
CORM-3, effectively reduced LPS-induced PMN rolling/
adhesion to hCMEC/D3 (Figure 6A), prevented activation of
AP-1 (Figure 6B), and significantly reduced expression of
VCAM-1 (Figure 6C).
DISCUSSION
The BBB represents a complex and unique structure of the
brain microcirculation with the luminal blood vessel
comprised of CVECs. During severe sepsis, systemic inflam-
mation likely subjects CVECs to the circulating proinflam-
matory mediators (e.g., LPS and cytokines) resulting in a
subsequent upregulation of the CVEC proinflammatory
phenotype [4,41]. In addition, due to decreased CPP and
reduced CBF observed in septic patients [1], CVECs are likely
exposed to the critical paracellular effects of rolling/adherent
PMNs. The current study was designed to assess CORM-3-
dependent modulation of LPS-induced inflammatory
responses in hCMEC/D3 cells, representing consistent and
well-characterized model of human brain microvascular
endothelium in vitro [36,55].
Recent studies in the field indicate that CO, a natural end
product of HO activity in mammalian tissues exhibits potent
anti-inflammatory effects [30,38,47]. Inhaled CO (200–
500 ppm) reduces inflammation and organ dysfunction not
only in animal models but also in humans with lung
inflammation and kidney transplantation (Phase I and II
clinical trials) [30]. Nevertheless the use of inhaled CO is
hampered by a rapid formation of toxic levels (>15%) of
HbCO resulting in decreased oxygen transport to tissues
[10,45,46].
Figure 3. CORM-3 suppresses activation of AP-1 in LPS-stimulated
hCMEC/D3. Confluent hCMEC/D3 were pretreated (Pre-) for two hours
with CORM-3 or iCORM-3 (200 lmol/L) and stimulated with LPS (1 lg/
mL) for 30 minutes. Subsequently, activation of AP-1 (c-Jun Ser63
phosphorylation levels) was assessed by ELISA. n = 4, *p < 0.05 as
compared to nontreated cells, #p < 0.05 as compared to LPS-stimulated
cells and LPS/iCORM-3-treated cells.
Figure 4. CORM-3 does not suppress activation of NF-jB in LPS-
stimulated hCMEC/D3. Confluent hCMEC/D3 were pretreated (Pre-) for
two hours with CORM-3 or iCORM-3 (200 lmol/L) and stimulated with
LPS (1 lg/mL) for one hour. Subsequently, activation of NF-jB (p65
Ser536 phosphorylation levels) was assessed by ELISA. n = 4, *p < 0.05
as compared to unstimulated cells.
Figure 5. CORM-3 suppresses JNK1/2 phosphorylation in LPS-stimulated
hCMEC/D3. Confluent hCMEC/D3 were pretreated (Pre-) for two hours
with CORM-3 or iCORM-3 (200 lmol/L) and stimulated with LPS (1 lg/
mL) for 30 minutes. Subsequently, activation of JNK1/2 (JNK1/2 phos-
phorylation levels) was assessed by western blotting followed by densi-
tometric analysis of the membranes. n = 4; *p < 0.05 as compared to
nontreated cells; #p < 0.05 as compared to LPS-stimulated cells;
##p < 0.05 as compared to LPS-stimulated cells and LPS/iCORM-3-treated
cells. Representative western blot image out of four experiments is shown.
F. Serizawa et al.
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Recently, transitional metal carbonyls, CORMs, have been
developed for delivery of CO in a controlled manner that
allows initial bypassing of the pulmonary circulation, and
having no or only moderate effects on HbCO formation (<3–
5% HbCO) [10,28,29,31]. It has been demonstrated that
CORM-derived CO offers antiapoptotic, antiatherosclerotic,
and anti-inflammatory effects in animal models of inflam-
mation/injury such as ischemia/reperfusion [14,16], pulmo-
nary hypertension [60], transplantation [2,48,50],
compartment syndrome [19], and sepsis/endotoxemia
[3,6,26]. In addition, survival of septic (i.e., LPS-challenged)
mice was markedly improved in animals that have been
pretreated and subsequently exposed to CO before/during
induction of endotoxemia [27].
The exact mechanism(s) of CO-dependent modulation of
inflammatory responses are largely unknown and often
controversial. Research aimed at understanding the mecha-
nisms of CO-mediated cell/organ protection suggests the role
of guanylate cyclase [33], MAPK [37], PI3K, and NF-jB
signaling pathways [3,17]. Hence, the actions mediated by
CO seem to invoke unique stimulus-dependent signaling
mechanism(s) in various cell types.
Despite of the complexity associated to CO-mediated cell
signaling recent evidence indicate that anti-inflammatory
effects of CORMs are largely attributed to their ability to
suppress leukocyte–endothelial cell adhesive interaction
resulting in reduced leukocyte recruitment to the affected
organs [3,26,52,54].
PMN recruitment to the inflamed tissues involves a series
of complex, yet well coordinated PMN-EC adhesive interac-
tions (i.e., PMN rolling and firm adhesion) and migration
across the endothelial barrier within the microvasculature
[20]. The current literature indicates that there is a general
consensus on the molecular determinants of PMN-EC
adhesive interactions, i.e., extensive characterization of the
adhesion molecules (e.g., P-selectin, E-selectin, ICAM-1, and
VCAM-1 on the vascular endothelium) and their ligands
(e.g., L-selectin, sialyl Lewis X, and b2- and b1-integrins on
PMNs), the kinetics of their expression after an induction
with various proinflammatory mediators (e.g., tumor
necrosis factor-alpha [TNF-a] or LPS), and their relative
roles in rolling and the development of strong adhesive
interactions [20,22,42,43].
With regard to the above, dimethyl sulfoxide (DMSO)-
soluble CO-releasing molecule, CORM-2, and water-soluble,
CORM-3, interfere with leukocyte accumulation in the liver of
septic mice [3] and skeletal muscle of compartment syn-
drome-challenged mice [19], respectively. In addition, it has
been demonstrated that water-soluble CORM-3 suppresses
PMN–HUVEC adhesive interaction by reducing CD11b
(aMb2-integrin) and L-selectin surface levels in platelet
activating factor-stimulated PMN [54]. Similarly, our previ-
ous findings also demonstrated that CORM-3 inhibits PMN
accumulation in the septic lung and suppresses LPS/Formyl-
Methionyl-Leucyl-Phenylalanine-induced PMN migration
across HUVECmonolayer through amechanism that requires
initial PMN activation (i.e., increased O2
 production) and
subsequent downregulation of PMN cell-surface levels of
serine protease, elastase [26]. Moreover, our recent findings
indicate that CORM-3 very effectively interferes with the
neutrophilic MPO activity and, in turn, suppresses MPO-
induced endothelial cell (HUVEC) activation (e.g., oxidative
stress) and dysfunction (e.g., permeability) [37]. Taken
Rolling
Adhesion
A
B
C
Figure 6. JNK inhibitor, SU3327, suppresses proinflammatory phenotype
in LPS-stimulated hCMEC/D3. Confluent hCMEC/D3 were pretreated
(Pre-) for 30 minutes with JNK inhibitor, SU3327 (25 nM/L) and stimu-
lated with LPS (1 lg/mL). Subsequently, hCMEC/D3 were assayed for
PMN rolling/adhesion (A), activation of AP-1 (B), and expression of
adhesion molecules E-selectin, ICAM-1 and VCAM-1 (C, D) under
experimental conditions described in Figures 1, 2, and 3, respectively.
n = 5, *p < 0.05 as compared to corresponding nontreated cells,
#p < 0.05 as compared to corresponding LPS-stimulated cells,
##p < 0.01 as compared to corresponding LPS-stimulated cells.
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together, these findings indicate that CORMs significantly
reduce the overall inflammatory potential of PMN, and,
therefore, interfere with the leukocyte (e.g., PMN)-dependent
propagation of the inflammatory response.
CORM-dependent modulation of endothelial cell inflam-
matory activation/dysfunction, however remains poorly
investigated and is quite controversial. In this regard, the
findings of our current study indicate that CORM-3 is
effective in suppressing VCAM-1 but not ICAM-1 or E-
selectin adhesion molecule expression (Figure 2). These
findings are consistent with the previous study by Urquhard
et al. [54] demonstrating that CORM-3 fails to suppress
ICAM-1 and E-selectin expression in TNF-a-stimulated
endothelial cells (HUVEC). On the contrary, the study by
Song et al. [49] demonstrated the efficacy of CORM-3 in
inhibition of E-selectin and VCAM-1 expression in TNF-a-
stimulated HUVEC. In addition, it has been shown that
CORM-2 (a DMSO-soluble CORM) reduces high-glucose-
induced expression of ICAM-1 in HUVEC [35]. Moreover,
CORM-2 appears to be very effective in reducing tissue levels
of ICAM-1 in septic liver and suppressing reactive oxygen
species production, NF-jB activation, and subsequent NF-
jB–dependent expression of ICAM-1, resulting in overall
reduced adhesion of PMN to LPS-stimulated HUVEC [3].
The discrepancies reported with CORMs may lay in
different experimental approaches employed, e.g., measuring
adhesion molecule levels in the tissue [3,52] vs cell culture
[49,54]; using western blot [3,52] vs flow cytometry [49,54]
vs cell ELISA [3]; nature and duration of inflammatory
stimulation (e.g., TNF-a [49,54] vs LPS [3]); and use of
different CO donors (e.g., CORM-2 [3,35,52] vs CORM-3
[49,54]) and various concentrations of CORMs (e.g., 10–
1000 lM [3,49,54]). In addition, endothelial cells obtained
from different vascular beds (e.g., HUVEC representing the
large blood vessels vs hCMEC/D3, representing brain
microvascular endothelial cells) may display different levels
of adhesion molecule expression and/or sensitivity to COR-
Ms, as well. Finally, differences in treating the cells/tissues
with CORMs (e.g., pretreatment with CORMs before stim-
ulation vs cotreatment with CORMs during stimulation vs
posttreatment with CORMs after stimulation) may also
result in different experimental outcomes. With regard to the
latter, our current study indicates that administration of
CORM-3 to hCMEC/D3 during stimulation with LPS
(cotreatment approach) failed to significantly suppress
LPS-induced upregulation of the proadhesive phenotype
(data not shown).
Despite obvious complexity in CO-mediated cell protec-
tion our current findings indicate that pretreatment of
hCMEC/D3 with CORM-3 preferentially interferes with
JNK1/2-signaling and subsequent activation of AP-1 (but
not NF-jB) resulting in suppressed hCMEC/D3 proadhesive
phenotype. These findings are consistent with the previously
published results indicating CO-mediated inhibition of JNK
signaling and subsequent selective suppression of one of the
major inflammation-relevant transcription factors, AP-1 (c-
Jun/c-Fos), but not NF-jB, resulting in reduced production
of IL-6 and IL-1b by LPS-stimulated macrophages [27]. Both
AP-1 and NF-jB transcription factors are well known for
their role in upregulation of the proinflammatory cytokine
and adhesion molecule expression [4,44]. MAP kinases (e.g.,
JNK), on the other hand, are critical for transducing LPS-
induced inflammatory signaling that activates AP-1 in various
cells (e.g., endothelial cells and macrophages) [8,18,27,37].
Relevant to this study, CO-dependent inhibition of LPS/toll-
like receptor-signaling has also been demonstrated [32].
The inability of CORM-3 (as oppose to CORM-2 [3]) in
the current study to interfere with LPS-induced activation of
NF-jB in hCMEC/D3 requires further investigation, how-
ever, may explain at least in part why CORM-3 failed to
suppress LPS-induced expression of E-selectin and ICAM-1
(molecules which expression is primarily controlled by NF-
jB activation). On the other hand, under experimental
conditions employed in the current study CORM-3-depen-
dent inhibition of JNK signaling appears to be responsible for
the suppression of AP-1 transcription factor that along with
NF-jB plays a critical role in LPS-induced upregulation of
adhesion molecule (e.g., VCAM-1) expression [40,53]. Our
current findings favor the latter scenario and indicate that
CORM-3-derived CO acts in a similar manner as JNK
inhibitors (i.e., SU3327) by suppressing LPS-induced expres-
sion of VCAM-1 and resulting in a subsequent reduction in
PMN adhesion to hCMEC/D3.
Thus, the unique finding of our study is that CORM-3-
suppressed VCAM-1 expression to effectively inhibit neutr-
ophilic leukocyte (PMN) adhesion. In addition, our findings
indicate a potential role for VCAM-1 as a prime molecule
involved in PMN rolling upon activated cerebrovascular
endothelium. Whether CORM-3 preferentially regulates
PMN adhesive interactions with CVECs through VCAM-1-
dependent mechanism, or also as a consequence of CORM-
3-dependent modulation of E-selectin affinity remains to be
determined.
In summary, our findings are the first to demonstrate the
efficacy of CORM-3 pretreatment in suppressing sepsis-
relevant activation (e.g., upregulation of the proadhesive
phenotype) of human-derived CVECs in vitro through a
mechanism involving JNK/AP-1 signaling.
PERSPECTIVE
Inflammatory activation of cerebrovascular endothelium
contributes to the impaired function of the BBB. We
demonstrate that increased human cerebrovascular endothe-
lial cell activation and proadhesive phenotype (i.e., expression
of VCAM-1) following stimulation with bacterial LPS are
F. Serizawa et al.
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suppressed by water-soluble CORM-3. These findings indi-
cate potential therapeutic applicability of CORMs in pre-
venting inflammatory activation of the vascular endothelium.
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